Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial-Reference-Cited by-同舟云学术

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial

Published:2020-11-21 Issue:24 Volume:9 Page:9419-9430
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med.

Author:

Ooki Akira¹^ORCID,Morita Satoshi²,Tsuji Akihito³,Iwamoto Shigeyoshi⁴,Hara Hiroki⁵,Tanioka Hiroaki⁶,Satake Hironaga⁷^ORCID,Kataoka Masato⁸,Kotaka Masahito⁹,Kagawa Yoshinori¹⁰,Nakamura Masato¹¹,Shingai Tatsushi¹²,Ishikawa Masashi¹³,Miyake Yasuhiro¹⁴,Suto Takeshi¹⁵,Hashiguchi Yojiro¹⁶,Yabuno Taichi¹⁷,Ando Masahiko¹⁸,Sakamoto Junichi¹⁹,Yamaguchi Kensei¹

Affiliation:

1. Department of Gastroenterological Chemotherapy Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Biomedical Statistics and Bioinformatics Kyoto University Kyoto Japan

3. Department of Medical Oncology Kagawa University Kita Japan

4. Department of Surgery Kansai Medical University Kouri Hospital Neyagawa Japan

5. Department of Gastroenterology Saitama Cancer Center Saitama Japan

6. Department of Clinical Oncology Kawasaki Medical School Kurashiki Japan

7. Cancer Treatment Center Kansai Medical University Hospital Osaka Japan

8. Department of Surgery National Hospital Organization Nagoya Medical Center Nagoya Japan

9. Gastrointestinal Cancer Center Sano Hospital Kobe Japan

10. Department of Surgery Kansai Rosai Hospital Amagasaki Japan

11. Comprehensive Cancer Center Aizawa Hospital Matsumoto Japan

12. Department of Surgery Osaka Saiseikai Senri Hospital Suita Japan

13. Department of Surgery Shikoku Central Hospital Shikokuchuo Japan

14. Department of Surgery Osaka Minato Central Hospital Osaka Japan

15. Department of Surgery Yamagata Prefectural Central Hospital Yamagata Japan

16. Department of Surgery Teikyo University School of Medicine Tokyo Japan

17. Department of Surgery Yokohama Municipal Citizen’s Hospital Yokohama Japan

18. Department of Advanced Medicine Nagoya University Hospital Nagoya Japan

19. Tokai Central Hospital Kakamigahara Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3564

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up;Van Cutsem E;Ann Oncol,2014

3. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

4. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

5. National Cancer Institute National Institutes of Health. U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention;Dermatology Practical & Conceptual;2024-07-31

2. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial;ESMO Open;2024-07

3. Pilot applications of GPT-4 in radiation oncology: Summarizing patient symptom intake and targeted chatbot applications;Radiotherapy and Oncology;2024-01

4. Central Nervous System-related Conditions and Associated Healthcare Resource Use Among Japanese nmCRPC Patients Based on Retrospective Claims Data;Journal of Health Economics and Outcomes Research;2023-10-31

5. Central Nervous System-related Conditions and Associated Healthcare Resource Use Among Japanese nmCRPC Patients Based on Retrospective Claims Data;Journal of Health Economics and Outcomes Research;2023-10-31